234 related articles for article (PubMed ID: 32251674)
1. DC591017, a phosphodiesterase-4 (PDE4) inhibitor with robust anti-inflammation through regulating PKA-CREB signaling.
Li H; Li J; Zhang X; Feng C; Fan C; Yang X; Zhang R; Zhu F; Zhou Y; Xu Y; Liu H; Tang W
Biochem Pharmacol; 2020 Jul; 177():113958. PubMed ID: 32251674
[TBL] [Abstract][Full Text] [Related]
2. Novel Phosphodiesterase 4 Inhibitor FCPR03 Alleviates Lipopolysaccharide-Induced Neuroinflammation by Regulation of the cAMP/PKA/CREB Signaling Pathway and NF-
Zou ZQ; Chen JJ; Feng HF; Cheng YF; Wang HT; Zhou ZZ; Guo HB; Zheng W; Xu JP
J Pharmacol Exp Ther; 2017 Jul; 362(1):67-77. PubMed ID: 28450469
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of phosphodiesterase-4 attenuates murine ulcerative colitis through interference with mucosal immunity.
Li H; Fan C; Feng C; Wu Y; Lu H; He P; Yang X; Zhu F; Qi Q; Gao Y; Zuo J; Tang W
Br J Pharmacol; 2019 Jul; 176(13):2209-2226. PubMed ID: 30883697
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 4B negatively regulates endotoxin-activated interleukin-1 receptor antagonist responses in macrophages.
Yang JX; Hsieh KC; Chen YL; Lee CK; Conti M; Chuang TH; Wu CP; Jin SC
Sci Rep; 2017 Apr; 7():46165. PubMed ID: 28383060
[TBL] [Abstract][Full Text] [Related]
5. FFPM, a PDE4 inhibitor, reverses learning and memory deficits in APP/PS1 transgenic mice via cAMP/PKA/CREB signaling and anti-inflammatory effects.
Guo H; Cheng Y; Wang C; Wu J; Zou Z; Niu B; Yu H; Wang H; Xu J
Neuropharmacology; 2017 Apr; 116():260-269. PubMed ID: 28065587
[TBL] [Abstract][Full Text] [Related]
6. Identification of phosphodiesterase-4 as the therapeutic target of arctigenin in alleviating psoriatic skin inflammation.
Li H; Zhang X; Xiang C; Feng C; Fan C; Liu M; Lu H; Su H; Zhou Y; Qi Q; Xu Y; Tang W
J Adv Res; 2021 Nov; 33():241-251. PubMed ID: 34603793
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment.
Zhang R; Li H; Zhang X; Li J; Su H; Lu Q; Dong G; Dou H; Fan C; Gu Z; Mu Q; Tang W; Xu Y; Liu H
Eur J Med Chem; 2021 Feb; 211():113004. PubMed ID: 33218684
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase-4D Knock-down in the Prefrontal Cortex Alleviates Chronic Unpredictable Stress-Induced Depressive-Like Behaviors and Memory Deficits in Mice.
Wang ZZ; Yang WX; Zhang Y; Zhao N; Zhang YZ; Liu YQ; Xu Y; Wilson SP; O'Donnell JM; Zhang HT; Li YF
Sci Rep; 2015 Jul; 5():11332. PubMed ID: 26161529
[TBL] [Abstract][Full Text] [Related]
9. DRM02, a novel phosphodiesterase-4 inhibitor with cutaneous anti-inflammatory activity.
Hunt DWC; Ivanova IA; Dagnino L
Tissue Barriers; 2020 Jul; 8(3):1765633. PubMed ID: 32479135
[TBL] [Abstract][Full Text] [Related]
10. PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways.
Kwak HJ; Park KM; Choi HE; Chung KS; Lim HJ; Park HY
Cell Signal; 2008 May; 20(5):803-14. PubMed ID: 18276108
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.
Dong C; Virtucio C; Zemska O; Baltazar G; Zhou Y; Baia D; Jones-Iatauro S; Sexton H; Martin S; Dee J; Mak Y; Meewan M; Rock F; Akama T; Jarnagin K
J Pharmacol Exp Ther; 2016 Sep; 358(3):413-22. PubMed ID: 27353073
[TBL] [Abstract][Full Text] [Related]
12. Oleic acid as the active agent and lipid matrix in cilomilast-loaded nanocarriers to assist PDE4 inhibition of activated neutrophils for mitigating psoriasis-like lesions.
Lin CY; Hsu CY; Elzoghby AO; Alalaiwe A; Hwang TL; Fang JY
Acta Biomater; 2019 May; 90():350-361. PubMed ID: 30951898
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1.
Korhonen R; Hömmö T; Keränen T; Laavola M; Hämäläinen M; Vuolteenaho K; Lehtimäki L; Kankaanranta H; Moilanen E
Br J Pharmacol; 2013 Aug; 169(7):1525-36. PubMed ID: 23849041
[TBL] [Abstract][Full Text] [Related]
14. Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod-induced psoriasis-like skin inflammation in mice.
Huang SW; Chen YJ; Wang ST; Ho LW; Kao JK; Narita M; Takahashi M; Wu CY; Cheng HY; Shieh JJ
J Dermatol Sci; 2016 Oct; 84(1):59-70. PubMed ID: 27449383
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
[TBL] [Abstract][Full Text] [Related]
16. UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy.
Wang L; Burmeister BT; Johnson KR; Baillie GS; Karginov AV; Skidgel RA; O'Bryan JP; Carnegie GK
Cell Signal; 2015 May; 27(5):908-22. PubMed ID: 25683917
[TBL] [Abstract][Full Text] [Related]
17. Hypersampsonone H attenuates ulcerative colitis via inhibition of PDE4 and regulation of cAMP/PKA/CREB signaling pathway.
Li Y; Wang M; Su J; Zhong R; Yin S; Zhao Z; Sun Z
Int Immunopharmacol; 2024 Feb; 128():111490. PubMed ID: 38218008
[TBL] [Abstract][Full Text] [Related]
18. Powerful relaxation of phosphodiesterase type 4 inhibitor rolipram in the pig and human bladder neck.
Ribeiro ASF; Fernandes VS; Martínez-Sáenz A; Martínez P; Barahona MV; Orensanz LM; Blaha I; Serrano-Margüello D; Bustamante S; Carballido J; García-Sacristán A; Prieto D; Hernández M
J Sex Med; 2014 Apr; 11(4):930-941. PubMed ID: 24754330
[TBL] [Abstract][Full Text] [Related]
19. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.
Perez-Aso M; Montesinos MC; Mediero A; Wilder T; Schafer PH; Cronstein B
Arthritis Res Ther; 2015 Sep; 17(1):249. PubMed ID: 26370839
[TBL] [Abstract][Full Text] [Related]
20. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
Schafer PH; Parton A; Capone L; Cedzik D; Brady H; Evans JF; Man HW; Muller GW; Stirling DI; Chopra R
Cell Signal; 2014 Sep; 26(9):2016-29. PubMed ID: 24882690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
